Healthcare
Hims & Hers Health, Inc.(HIMS)
Live Price
Offline$35.47
+11.23% today
1Y Change
-20.41%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $5.97B
- Revenue Growth
- +59.0%
- EPS Growth
- -1.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hims & Hers Health, Inc. (HIMS) is a Healthcare stock with a market cap of $5.97B and listed on NYSE. The stock last traded around $35.47 and down 20.4% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +59.0%, EPS growth of -1.7%, a dividend yield of 0.0%. What stands out right now is revenue +59.0%, EPS -1.7%, free cash flow -62.7% with operating margin 4.5% and ROIC 6.0%. Valuation already assumes a fairly strong business story at P/E 48.1 and price/sales 2.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines HIMS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+59.0% vs +7.6% peer median
Operating Margin
Below sector median
+4.5% vs +19.4% peer median
P/E
Above sector median
48.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +59.0% and EPS is at -1.7%, with operating margin around 4.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -3.4% | +6.9% | +0.9% |
2026 Feb 23, 2026 | +250.0% | -0.3% | +6.3% | +44.8% |
2025 Nov 3, 2025 | -33.3% | -3.6% | -7.5% | -18.2% |
Benchmark Edge
HIMS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HIMS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HIMS Max Drawdown
-78.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HIMS and SPY.
Company Overview
Hims & Hers Health, Inc.
New York Stock Exchange
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
- Leadership
- Andrew Dudum
- IPO Date
- Sep 13, 2019
- Employees
- 1.6k
- Street Address
- 2269 Chestnut Street
- Mailing
- San Francisco, CA, 94123
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 851 0195
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 48.1
- EV/EBITDA
- 43.6
- Price/Sales
- 2.5
- Price/Book
- 11.4
Growth
- Revenue
- +59.0%
- EPS
- -1.7%
- Free Cash Flow
- -62.7%
Profitability
- Gross Margin
- 73.8%
- Operating Margin
- 4.5%
- Net Margin
- 5.5%
- ROE
- 23.0%
- ROIC
- 6.0%
Balance Sheet
- Debt/Equity
- 2.34
- Current Ratio
- 1.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.